Dr. Brufsky on Ways to Mitigate Cost Before Biosimilars Reach US Market
December 18th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses cost mitigation practices that can be implemented before more biosimilars reach the United States market.
Read More
Dr. Brufsky Addresses Biosimilar Skepticism
December 5th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, addresses biosimilar skepticism.
Read More
Dr. Brufsky on Reducing the Cost of Care in Breast Oncology
November 17th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses reducing the cost of care in breast oncology.
Read More
Dr. Brufsky Discusses Reasons to Use Biosimilars in Oncology
November 6th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses reasons to use biosimilars in oncology.
Read More
Dr. Brufsky on Multiparametric Genomic Assays in Breast Cancer
April 28th 2018Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses multiparametric assays in breast cancer.
Read More
Dr. Brufsky Discusses Biosimilar Development and Approval
April 9th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the development and approval of biosimilars in oncology.
Read More
Dr. Brufsky on Biosimilars Being Explored in Oncology
March 28th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses biosimilars currently being explored in cancer.
Read More
Dr. Brufsky on Challenges Facing Biosimilars in Breast Cancer
March 16th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses challenges facing biosimilars for the treatment of patients with breast cancer.
Read More
Dr. Brufsky on the FDA Approval of Olaparib in BRCA+ Breast Cancer
January 12th 2018Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses the FDA approval of olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings.
Read More
Dr. Brufsky on Implementing Pertuzumab in HER2+ Breast Cancer
December 8th 2017Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, on implementing pertuzumab (Perjeta) in the treatment of patients of HER2-positive breast cancer.
Read More
Dr. Brufsky Discusses Pertuzumab in HER2+ Breast Cancer
November 14th 2017Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.
Read More
Dr. Brufsky on CDK 4/6 Inihibitors in Neoadjuvant Breast Cancer Treatment
June 29th 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.
Read More
Dr. Brufsky Discusses Resistance to HER2-Targeted Therapies
May 23rd 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses resistance to HER2-targeted therapy in breast cancer.
Read More